Streetbeat News

ASND

Ascendis Pharma A/S

https://ascendispharma.com

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Several large-cap stocks experienced significant declines last week. Notable losers include Summit Therapeutics, Kaspi.kz, BioMarin Pharmaceutical, Rivian Automotive, FedEx, BioNTech, Arthur J. Gallagher, Chewy, Novo Nordisk, and Murphy USA. Factors such as financial results, analyst reports, and competitive pressures contributed to these declines.

Portfolio Pulse from Lekha Gupta

September 22, 2024 | 9:04 pm

Ascendis Pharma has priced a public offering of 2 million ADSs at $150 each, raising approximately $281.3 million. The proceeds will be used for commercial and clinical development activities, regulatory approvals, and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:55 am

Ascendis Pharma has announced a public offering of $300 million of American Depositary Shares (ADSs), with an option for underwriters to purchase an additional $45 million. This move is likely to impact the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:05 pm

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and raised the price target from $264 to $289.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:42 pm

Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma and increased the price target from $178 to $207.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:21 pm

Evercore ISI Group has maintained an Outperform rating on Ascendis Pharma and raised its price target from $191 to $205, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:57 pm

Oppenheimer analyst Leland Gershell has reiterated an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $180 to $190.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:49 pm

Goldman Sachs analyst Paul Choi has maintained a Buy rating on Ascendis Pharma and increased the price target from $180 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:26 pm

Ascendis Pharma's new trial data for TransCon CNP, a treatment for dwarfism, shows promising results, posing a competitive threat to BioMarin's Voxzogo. BioMarin's stock has dropped due to this potential competition, despite its first-mover advantage and ongoing efforts to expand Voxzogo's market presence.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 7:12 pm

U.S. stocks showed mixed performance with the Nasdaq Composite falling around 1%. Energy shares rose by 1.1%, while information technology shares fell by 0.9%. Notable stock movements included NuCana plc surging 151% after positive trial data, Ascendis Pharma rising 17% on trial results, and Nuvalent gaining 28% after announcing a public offering and positive program results. Instil Bio shares plunged 25% due to strategic announcements, Sterling Bancorp fell 17% after announcing a sale and dissolution plan, and iTeos Therapeutics dropped 20% following interim data release.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.